According to a recent LinkedIn post from Visby Medical, the company is seeing what it describes as strong momentum in its distribution partnership with DoorDash for its FDA-authorized at-home PCR sexual health test. The post cites month-over-month demand growth ranging from 50% to 150% and notes that DoorDash is emerging as a key channel for rapid, private testing access.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post indicates that within about two weeks, the at-home test is expected to be available in nearly 2,000 ZIP codes, reaching an estimated 15–20% of U.S. middle-to-high income households, with delivery times reportedly as short as 30 minutes. If sustained, this geographic and demographic expansion could support higher testing volumes and help Visby build consumer brand recognition in the at-home diagnostics segment.
Customer traction metrics highlighted in the post include an average product rating of 4.8 stars and a net promoter score above 70, with DoorDash users described as twice as likely to purchase compared with other channels. For investors, these reported engagement figures may signal early product-market fit and suggest that on-demand delivery platforms could be a scalable distribution model for Visby’s offerings.
The post also references collaboration with partners such as Everlywell and Google Cloud as part of a broader effort to make fast, lab-quality STI testing more accessible. These partnerships, combined with DoorDash-enabled reach, may enhance Visby Medical’s competitive position in digital health and at-home diagnostics, potentially supporting future revenue growth and strengthening its appeal in a consolidating health-tech ecosystem.